Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

EQS-News: Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation


EQS-News: Krones AG / Key word(s): Acquisition
Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation

09.11.2022 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

9 November 2022

Corporate News Release

 


Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation
 

Krones, a leading manufacturer of filling and packaging solutions, has acquired 80.5% of R+D Custom Automation LLC (R+D) with effect from 8 November 2022. Based in Wisconsin, USA, R+D supplies machinery and equipment for the production and filling of containers for the pharmaceutical industry. As a full-service system integrator and specialised equipment manufacturer, R+D has been providing custom engineering solutions to the life science industry for over 40 years.

In the 2021 fiscal year, the company generated revenue of some US$43 million with a workforce of more than 60 employees. The purchase price for the stake in R+D is in the mid double-digit millions of US dollars and is met out of available cash funds.

Krones has an option to buy the remaining 19.5% of the shares in R+D, which remain with the current management.

The acquisition of R+D marks a continuation of Krones’ strategy of additional growth outside the beverage industry. It strengthens Krones’ activities in the attractive life science and pharmaceutical market, which shows above-average growth. In R+D, Krones also gains a highly experienced team with innovative solutions and good customer relationships with established pharmaceutical groups.

 

 

Contact:

Olaf Scholz

Head of Investor Relations, Krones AG

Tel.: +49 9401 70-1169

Email: [email protected]

 

 



09.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Krones AG
Böhmerwaldstraße 5
93073 Neutraubling
Germany
Phone: +49 (0)9401 701169
Fax: +49 (0)9401 709 1 1169
E-mail: [email protected]
Internet: www.krones.com
ISIN: DE0006335003
WKN: 633500
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1482587

 
End of News EQS News Service

1482587  09.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1482587&application_name=news&site_id=sharewise

Krones AG Stock

€129.40
0.000%
There is no change in the price for Krones AG today.

Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments